April 26, 2018
InSysBio LLC (www.insysbio.com) – pioneer in Quantitative Systems Pharmacology (QSP) modeling and simulation for drug development – announced today further collaboration with GSK - one of the world’s leading research-based pharmaceutical and healthcare companies - to expand the previously developed QSP model of asthma.
The companies together have constructed a complex asthma model which facilitated the investigation of novel medicines and combination therapy scenarios. GSK has chosen InSysBio as a partner to implement a further expansion of the existing model. This will include new targets and clinical trial data to be able simulate more asthma treatment scenarios.
“We chose to work with InSysBio because of their rich experience in QSP modeling and fundamental knowledge in the field. Through this partnership, we hope to continue to improve drug development in asthma”, David Fairman, Senior Director Clinical Pharmacology Modelling and Simulation, GSK, Lourdes Cucurull-Sanchez, Manager Target Sciences, GSK.
“We are very pleased that GSK decided to continue work with us. It means InSysBio has shown itself as a partner with significant expertise and strength in QSP”, Oleg Demin Jr, Head of Business Development, InSysBio.
About InSysBio
InSysBio (formerly Institute for System Biology Moscow) was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of quantitative systems pharmacology (QSP) modeling. InSysBio’s innovative approach has already become a part of the drug development process implemented by our strategic partners: nowadays there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. The company has published a lot of scientific studies in various therapeutic areas. InSysBio team is developing software and tools for QSP and continuously improves methods for biological modeling. For more information about InSysBio, its solutions and services, visit www.insysbio.com.
| ← | September 2024 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
| ||||||
|
2
|
3
|
4
1.
04 Sep 2024 16:07
Now B cells model reflects the current views on the processes
InSysBio launches Immune Response Template (IRT) version 3.6.3. IRT represents a QSP platform of immune system, simultaneously, being a tool for development of models related to immune system
|
5
|
6
|
7
|
8
|
|
9
|
10
1.
10 Sep 2024 18:36
InSysBio team to publish the new article in PSPJournal
The new article "Quantitative systems pharmacology model of α-synuclein pathology in Parkinson's disease-like mouse for investigation of passive immunotherapy mechanisms" by Olga Ivanova and Tatiana Karelina was published in PSPJournal at the end of August 2024
|
11
1.
11 Sep 2024 15:25
InSysBio to take part in ACoP 2024
InSysBio announces its participation in the 15th American Conference on Pharmacometrics (ACoP). Oleg Demin Jr, Scientific Director, Oncology & Immuno-Oncology, will be a co-chair and speaker of the session "Advancing QSP: From Virtual Patient To Digital Twin". InSysBio team is going to present its modeling services & software to optimize drug development at the Booth #11 and 9 posters in frames of the Conference
|
12
|
13
|
14
|
15
|
|
16
|
17
|
18
|
19
|
20
|
21
|
22
|
|
23
|
24
|
25
|
26
|
27
|
28
|
29
|
|
30
| ||||||
Thank you for your message! We will get back to you shortly.
